We’re excited to announce that we will be hosting a booth at the 39th Annual Society for Immunotherapy of Cancer (SITC) meeting in Houston, Texas, this November 6-10. Join us at booth 1121 to learn more about our ultrasensitive MRD testing technology and how it empowers clinicians and researchers to monitor cancer treatment with precision.
Visit our booth where you’ll have the opportunity to:
- Explore Haystack MRD™: See how our tumor-informed liquid biopsy technology offers an ultrasensitive approach to detecting minimal residual disease, assessing treatment response, and monitoring for recurrence
- Engage with our experts: Meet our team of specialists and discuss how Haystack MRD can enhance your clinical practice or research studies
- Discover opportunities to work together: We’re eager to connect with pharmaceutical companies and clinical researchers to explore how our MRD technology can support ongoing and future projects
Don’t miss the chance to see how Haystack MRD is advancing precision oncology. We look forward to meeting you at booth 1121!
Learn more about the SITC Annual Meeting here.
About Haystack MRD
Next-generation ctDNA detection with exquisite sensitivity and specificity for precise MRD reporting
Haystack MRD is a tumor-informed ctDNA detection test for postsurgical measurement of residual disease in solid tumor settings. Exquisite sensitivity and specificity translate to better MRD detection for greater confidence when making key clinical decisions.
Purpose-built MRD technology developed by pioneers of cancer research
Haystack MRD was designed specifically for ultrasensitive ctDNA detection when testing for residual or recurrent disease. Better sensitivity means that patients are more likely to receive the right treatment at the right time, which can significantly improve outcomes and quality of life for patients who have been diagnosed with cancer.
Experience the power of Quest
Haystack MRD leverages Quest’s credentialed staff, labs, logistics, service, reporting, and technology for a streamlined testing experience. Plus, from early detection screening to diagnosis, monitoring, and beyond, Quest offers routine to advanced testing for every stage of cancer. Experience the efficiency of working with a single lab to improve the quality and speed of cancer care.
